Breast cancer can be divided into three clinical subtypes, featured by expression of the estrogen receptor (ER), the progesterone receptor (PR), or amplification of the HER-2/NEU gene encoding an Erb-type receptor tyrosine kinase, which can be all treated with chemotherapy or specific tyrosine kinase inhibitors. Here, PGR is linked to breast cancer.